Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
30 Apr 24
DEFA14A
Additional proxy soliciting materials
30 Apr 24
DEF 14A
Definitive proxy
30 Apr 24
424B5
Prospectus supplement for primary offering
17 Apr 24
8-K
TScan Therapeutics Announces Launch of $125 million Proposed
17 Apr 24
FWP
Free writing prospectus
17 Apr 24
424B5
Prospectus supplement for primary offering
16 Apr 24
8-K
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
16 Apr 24
EFFECT
Notice of effectiveness
15 Apr 24
10-K/A
2023 FY
Annual report (amended)
10 Apr 24
8-K
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert
8 Apr 24
S-3
Shelf registration
6 Mar 24
S-8
Registration of securities for employees
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
6 Mar 24
8-K
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
29 Jan 24
8-K
Regulation FD Disclosure
11 Dec 23
8-K
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
7 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
10 Aug 23
8-K
Departure of Directors or Certain Officers
24 Jul 23
8-K
TScan Therapeutics Announces Transition of Chief Financial Officer
29 Jun 23
S-8
Registration of securities for employees
16 Jun 23
8-K
Departure of Directors or Certain Officers
15 Jun 23
DEFA14A
Additional proxy soliciting materials
2 Jun 23
8-K
TScan Therapeutics Announces Launch of Proposed Public Offering
31 May 23
8-K
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
31 May 23
424B5
Prospectus supplement for primary offering
26 May 23
FWP
Free writing prospectus
26 May 23
424B5
Prospectus supplement for primary offering
25 May 23
8-K
Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation
17 May 23
EFFECT
Notice of effectiveness
17 May 23
EFFECT
Notice of effectiveness
17 May 23
8-K
Other Events
16 May 23
424B5
Prospectus supplement for primary offering
16 May 23
AW
Withdrawal of amendment
16 May 23
S-3/A
Shelf registration (amended)
15 May 23
S-3/A
Shelf registration (amended)
15 May 23
Latest ownership filings
SC 13G
Cormorant Asset Management, LP
29 Apr 24
SC 13D/A
BAKER BROS. ADVISORS LP
23 Apr 24
4
JULIAN BAKER
23 Apr 24
4
Weston Nichols
23 Apr 24
SC 13G/A
K2 HealthVentures Equity Trust LLC
14 Feb 24
SC 13G/A
GV 2017, L.P.
9 Feb 24
SC 13G/A
Pitango HealthTech Fund I, L.P.
8 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
Jason Amello
2 Feb 24
3
Jason Amello
2 Feb 24
4
TIMOTHY J BARBERICH
21 Dec 23
4
Barbara Klencke
18 Dec 23
4
Keith Woods
8 Dec 23
3
Keith Woods
8 Dec 23
4
Leiden Dworak
24 Jul 23
3
Leiden Dworak
24 Jul 23
4
TIMOTHY J BARBERICH
15 Jun 23
4
Debora Barton
15 Jun 23
4
Katina Dorton
15 Jun 23
4
Gabriela Gruia
15 Jun 23
4
Barbara Klencke
15 Jun 23
4
Brian M. Silver
15 Jun 23
4
Gavin MacBeath
15 Jun 23
4
ZORAN ZDRAVESKI
15 Jun 23
4
JULIAN BAKER
15 Jun 23
SC 13G
ADAGE CAPITAL PARTNERS GP, L.L.C.
12 Jun 23
SC 13G/A
BlackRock Inc.
8 Jun 23
4
TIMOTHY J BARBERICH
6 Jun 23
SC 13G
BIOTECHNOLOGY VALUE FUND L P
5 Jun 23
SC 13G
EcoR1 Capital, LLC
5 Jun 23
3
Initial statement of insider ownership
5 Jun 23
4
Weston Nichols
2 Jun 23
3
Weston Nichols
2 Jun 23
SC 13G
Lynx1 Capital Management LP
2 Jun 23
SC 13D/A
BAKER BROS. ADVISORS LP
2 Jun 23
4
JULIAN BAKER
2 Jun 23
144
Notice of proposed sale of securities
15 May 23
4
Barbara Klencke
10 Apr 23
3
Barbara Klencke
10 Apr 23
SC 13G/A
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
14 Feb 23